Enfortumab Vedotin-ejfv Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Enfortumab Vedotin-ejfv Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
87
Registered trials
200
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Enfortumab Vedotin-ejfv can convert its Antibody drug conjugate (ADC) profile and Tubulin x nectin-4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Enfortumab Vedotin-ejfv (query alias: enfortumab vedotin) |
|---|---|
| Modality / target | Antibody drug conjugate (ADC); Tubulin x nectin-4; Tubulin inhibitors, nectin-4 inhibitors |
| Highest global status | Approved |
| Originator | Astellas Pharma, Inc. |
| Active developers | Seagen, Inc., Merck Sharp & Dohme Corp., Astellas Pharma, Inc. |
The MCP disease footprint includes Muscle Invasive Bladder Carcinoma, Unresectable Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07647289 | Phase 2 | Recruiting | 58 | 1-Year Event-Free Survival (EFS) Rate |
| NCT07663747 | Phase 2 | Not yet recruiting | 56 | Estimated 2-year bladder-intact event-free survival (BI-EFS) for the intention-to-treat population, measured from day 1 of treatment until the moment of analysis |
| NCT07643519 | Phase 2 | Not yet recruiting | 39 | Clinical complete response rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
Phase 3; n=595; evaluation: not stated. Reported fields: EFS(Median): Hazard Ratio (HR) = 0.40(95% CI, 0.28 - 0.57), P-Value = <0.0001; EFS(Median) = 15.7 Months (95% Confidence Interval, 10.3 - 20.5); EFS(Median): Hazard Ratio (HR) = 0.40(95% CI, 0.28 - 0.57), P-Value = <0.0001
Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
Not Applicable; n=79; evaluation: Positive. Reported fields: CR = 13.9 %
Real-world retrospective analysis of outcomes, treatment duration, dose intensity, and safety of enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.
Not Applicable; n=78; evaluation: Negative. Reported fields: Discontinuation rates = 97.0 % ; Discontinuation rates = 91.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Enfortumab Vedotin-ejfv addresses Muscle Invasive Bladder Carcinoma, Unresectable Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2007-01-08 | Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer | Not disclosed | US$12.0M upfront; US$250.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- CLDN18.2 assay, cutoff, and intratumoral heterogeneity
- Payload-related toxicity and dose intensity
- Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
